{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T12:04:56Z","timestamp":1790337896594,"version":"4.1.0"},"reference-count":61,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T00:00:00Z","timestamp":1785110400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T00:00:00Z","timestamp":1785110400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur Arch Otorhinolaryngol"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1007\/s00405-026-10470-y","type":"journal-article","created":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T12:14:10Z","timestamp":1785154450000},"page":"6683-6701","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Characterizing risk groups in papillary thyroid carcinoma through T-Cell mediated tumor cell killing-related genes: a pathway to therapeutic predictions"],"prefix":"10.1007","volume":"283","author":[{"given":"Yan","family":"Zhong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guanghui","family":"Ren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiming","family":"Sang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-6570-2771","authenticated-orcid":false,"given":"Jizong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,27]]},"reference":[{"key":"10470_CR1","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1007\/s10552-018-1023-2","volume":"29","author":"BC James","year":"2018","unstructured":"James BC, Mitchell JM, Jeon HD, Vasilottos N et al (2018) An update in international trends in incidence rates of thyroid cancer, 1973\u20132007. Cancer Causes Control 29:465\u2013473. https:\/\/doi.org\/10.1007\/s10552-018-1023-2","journal-title":"Cancer Causes Control"},{"key":"10470_CR2","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1016\/s2213-8587(22)00035-3","volume":"10","author":"M Pizzato","year":"2022","unstructured":"Pizzato M, Li M, Vignat J, Laversanne M et al (2022) The epidemiological landscape of thyroid cancer worldwide: GLOBOCAN estimates for incidence and mortality rates in 2020. Lancet Diabetes Endocrinol 10:264\u2013272. https:\/\/doi.org\/10.1016\/s2213-8587(22)00035-3","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10470_CR3","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1038\/nrendo.2016.110","volume":"12","author":"CM Kitahara","year":"2016","unstructured":"Kitahara CM, Sosa JA (2016) The changing incidence of thyroid cancer. Nat Rev Endocrinol 12:646\u2013653. https:\/\/doi.org\/10.1038\/nrendo.2016.110","journal-title":"Nat Rev Endocrinol"},{"key":"10470_CR4","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1007\/s00268-018-4479-z","volume":"42","author":"Y Ito","year":"2018","unstructured":"Ito Y, Miyauchi A, Kihara M, Fukushima M et al (2018) Overall Survival of Papillary Thyroid Carcinoma Patients: A Single-Institution Long-Term Follow-Up of 5897 Patients. World J Surg 42:615\u2013622. https:\/\/doi.org\/10.1007\/s00268-018-4479-z","journal-title":"World J Surg"},{"key":"10470_CR5","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1016\/j.clinthera.2014.03.016","volume":"36","author":"CS Grant","year":"2014","unstructured":"Grant CS (2014) Papillary thyroid cancer: strategies for optimal individualized surgical management. Clin Ther 36:1117\u20131126. https:\/\/doi.org\/10.1016\/j.clinthera.2014.03.016","journal-title":"Clin Ther"},{"key":"10470_CR6","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.2147\/cmar.S159583","volume":"10","author":"H Ren","year":"2018","unstructured":"Ren H, Shen Y, Hu D, He W et al (2018) Co-existence of BRAF(V600E) and TERT promoter mutations in papillary thyroid carcinoma is associated with tumor aggressiveness, but not with lymph node metastasis. Cancer Manag Res 10:1005\u20131013. https:\/\/doi.org\/10.2147\/cmar.S159583","journal-title":"Cancer Manag Res"},{"key":"10470_CR7","doi-asserted-by":"publisher","first-page":"236","DOI":"10.14639\/0392-100x-n1412","volume":"41","author":"A Ywata de Carvalho","year":"2021","unstructured":"Ywata de Carvalho A, Kohler HF, Gomes CC, Vartanian JG, Kowalski LP (2021) Predictive factors for recurrence of papillary thyroid carcinoma: analysis of 4,085 patients. Acta Otorhinolaryngol Ital 41:236\u2013242. https:\/\/doi.org\/10.14639\/0392-100x-n1412","journal-title":"Acta Otorhinolaryngol Ital"},{"key":"10470_CR8","doi-asserted-by":"publisher","first-page":"1288527","DOI":"10.3389\/fendo.2023.1288527","volume":"14","author":"J Du","year":"2023","unstructured":"Du J, Yang Q, Sun Y, Shi P et al (2023) Risk factors for central lymph node metastasis in patients with papillary thyroid carcinoma: a retrospective study. Front Endocrinol (Lausanne) 14:1288527. https:\/\/doi.org\/10.3389\/fendo.2023.1288527","journal-title":"Front Endocrinol (Lausanne)"},{"key":"10470_CR9","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1038\/nrc.2016.36","volume":"16","author":"SL Topalian","year":"2016","unstructured":"Topalian SL, Taube JM, Anders RA, Pardoll DM (2016) Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy. Nat Rev Cancer 16:275\u2013287. https:\/\/doi.org\/10.1038\/nrc.2016.36","journal-title":"Nat Rev Cancer"},{"key":"10470_CR10","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1093\/annonc\/mdy551","volume":"30","author":"KM Heinhuis","year":"2019","unstructured":"Heinhuis KM, Ros W, Kok M, Steeghs N et al (2019) Enhancing antitumor response by combining immune checkpoint inhibitors with chemotherapy in solid tumors. Ann Oncol 30:219\u2013235. https:\/\/doi.org\/10.1093\/annonc\/mdy551","journal-title":"Ann Oncol"},{"key":"10470_CR11","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1038\/s41392-020-00449-4","volume":"6","author":"T Tang","year":"2021","unstructured":"Tang T, Huang X, Zhang G, Hong Z et al (2021) Advantages of targeting the tumor immune microenvironment over blocking immune checkpoint in cancer immunotherapy. Signal Transduct Target Ther 6:72. https:\/\/doi.org\/10.1038\/s41392-020-00449-4","journal-title":"Signal Transduct Target Ther"},{"key":"10470_CR12","doi-asserted-by":"publisher","first-page":"4041","DOI":"10.1111\/cas.14634","volume":"111","author":"K Zhang","year":"2020","unstructured":"Zhang K, Zhang L, Mi Y, Tang Y et al (2020) A ceRNA network and a potential regulatory axis in gastric cancer with different degrees of immune cell infiltration. Cancer Sci 111:4041\u20134050. https:\/\/doi.org\/10.1111\/cas.14634","journal-title":"Cancer Sci"},{"key":"10470_CR13","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1126\/science.aao1710","volume":"359","author":"D Pan","year":"2018","unstructured":"Pan D, Kobayashi A, Jiang P, de Ferrari L et al (2018) A major chromatin regulator determines resistance of tumor cells to T cell-mediated killing. Science 359:770\u2013775. https:\/\/doi.org\/10.1126\/science.aao1710","journal-title":"Science"},{"key":"10470_CR14","doi-asserted-by":"publisher","first-page":"931647","DOI":"10.3389\/fendo.2022.931647","volume":"13","author":"S Banerjee","year":"2022","unstructured":"Banerjee S, Nahar U, Dahiya D, Mukherjee S et al (2022) Role of cytotoxic T cells and PD-1 immune checkpoint pathway in papillary thyroid carcinoma. Front Endocrinol (Lausanne) 13:931647. https:\/\/doi.org\/10.3389\/fendo.2022.931647","journal-title":"Front Endocrinol (Lausanne)"},{"key":"10470_CR15","doi-asserted-by":"publisher","first-page":"636568","DOI":"10.3389\/fimmu.2021.636568","volume":"12","author":"K Dhatchinamoorthy","year":"2021","unstructured":"Dhatchinamoorthy K, Colbert JD, Rock KL (2021) Cancer Immune Evasion Through Loss of MHC Class I Antigen Presentation. Front Immunol 12:636568. https:\/\/doi.org\/10.3389\/fimmu.2021.636568","journal-title":"Front Immunol"},{"key":"10470_CR16","doi-asserted-by":"publisher","unstructured":"Han PZ, Ye WD, Yu PC, Tan LC et al (2024) A distinct tumor microenvironment makes anaplastic thyroid cancer more lethal but immunotherapy sensitive than papillary thyroid cancer. JCI Insight 9. https:\/\/doi.org\/10.1172\/jci.insight.173712","DOI":"10.1172\/jci.insight.173712"},{"key":"10470_CR17","doi-asserted-by":"publisher","first-page":"637826","DOI":"10.3389\/fendo.2020.637826","volume":"11","author":"E Menicali","year":"2020","unstructured":"Menicali E, Guzzetti M, Morelli S, Moretti S, Puxeddu E (2020) Immune Landscape of Thyroid Cancers: New Insights. Front Endocrinol (Lausanne 11:637826. https:\/\/doi.org\/10.3389\/fendo.2020.637826","journal-title":"Front Endocrinol (Lausanne"},{"key":"10470_CR18","doi-asserted-by":"publisher","first-page":"4200","DOI":"10.1093\/bioinformatics\/btz210","volume":"35","author":"B Ru","year":"2019","unstructured":"Ru B, Wong CN, Tong Y, Zhong JY et al (2019) TISIDB: an integrated repository portal for tumor-immune system interactions. Bioinformatics 35:4200\u20134202. https:\/\/doi.org\/10.1093\/bioinformatics\/btz210","journal-title":"Bioinformatics"},{"key":"10470_CR19","doi-asserted-by":"publisher","first-page":"868480","DOI":"10.3389\/fimmu.2022.868480","volume":"13","author":"WF Hong","year":"2022","unstructured":"Hong WF, Liu MY, Liang L, Zhang Y et al (2022) Molecular Characteristics of T Cell-Mediated Tumor Killing in Hepatocellular Carcinoma. Front Immunol 13:868480. https:\/\/doi.org\/10.3389\/fimmu.2022.868480","journal-title":"Front Immunol"},{"key":"10470_CR20","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1007\/978-1-4939-0512-6_3","volume":"1150","author":"O Nikolayeva","year":"2014","unstructured":"Nikolayeva O, Robinson MD (2014) edgeR for differential RNA-seq and ChIP-seq analysis: an application to stem cell biology. Methods Mol Biol 1150:45\u201379. https:\/\/doi.org\/10.1007\/978-1-4939-0512-6_3","journal-title":"Methods Mol Biol"},{"key":"10470_CR21","doi-asserted-by":"publisher","first-page":"2056","DOI":"10.1007\/s10528-023-10359-z","volume":"61","author":"YS Zhu","year":"2023","unstructured":"Zhu YS, Yan H, Mo TT, Zhang JN, Jiang C (2023) Identification of Diagnostic Markers in Synovial Tissue of Osteoarthritis by Weighted Gene Coexpression Network. Biochem Genet 61:2056\u20132075. https:\/\/doi.org\/10.1007\/s10528-023-10359-z","journal-title":"Biochem Genet"},{"key":"10470_CR22","doi-asserted-by":"publisher","first-page":"2207","DOI":"10.1007\/s11010-022-04647-2","volume":"478","author":"X Yang","year":"2023","unstructured":"Yang X, Su X, Wang Z, Yu Y et al (2023) ULBP2 is a biomarker related to prognosis and immunity in colon cancer. Mol Cell Biochem 478:2207\u20132219. https:\/\/doi.org\/10.1007\/s11010-022-04647-2","journal-title":"Mol Cell Biochem"},{"key":"10470_CR23","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1186\/s12886-024-03441-6","volume":"24","author":"Z Zhan","year":"2024","unstructured":"Zhan Z, Lin K, Wang T (2024) Construction of oxidative phosphorylation-related prognostic risk score model in uveal melanoma. BMC Ophthalmol 24:204. https:\/\/doi.org\/10.1186\/s12886-024-03441-6","journal-title":"BMC Ophthalmol"},{"key":"10470_CR24","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1016\/j.celrep.2016.12.019","volume":"18","author":"P Charoentong","year":"2017","unstructured":"Charoentong P, Finotello F, Angelova M, Mayer C et al (2017) Pan-cancer Immunogenomic Analyses Reveal Genotype-Immunophenotype Relationships and Predictors of Response to Checkpoint Blockade. Cell Rep 18:248\u2013262. https:\/\/doi.org\/10.1016\/j.celrep.2016.12.019","journal-title":"Cell Rep"},{"key":"10470_CR25","doi-asserted-by":"publisher","first-page":"e107468","DOI":"10.1371\/journal.pone.0107468","volume":"9","author":"P Geeleher","year":"2014","unstructured":"Geeleher P, Cox N, Huang RS (2014) pRRophetic: an R package for prediction of clinical chemotherapeutic response from tumor gene expression levels. PLoS ONE 9:e107468. https:\/\/doi.org\/10.1371\/journal.pone.0107468","journal-title":"PLoS ONE"},{"key":"10470_CR26","doi-asserted-by":"publisher","first-page":"331","DOI":"10.3892\/ijo.2019.4820","volume":"55","author":"J Ye","year":"2019","unstructured":"Ye J, Qi L, Chen K, Li R et al (2019) Metformin induces TPC-1 cell apoptosis through endoplasmic reticulum stress-associated pathways in vitro and in vivo. Int J Oncol 55:331\u2013339. https:\/\/doi.org\/10.3892\/ijo.2019.4820","journal-title":"Int J Oncol"},{"key":"10470_CR27","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1016\/j.biopha.2018.07.046","volume":"106","author":"L Luo","year":"2018","unstructured":"Luo L, Xia L, Zha B, Zuo C et al (2018) miR-335-5p targeting ICAM-1 inhibits invasion and metastasis of thyroid cancer cells. Biomed Pharmacother 106:983\u2013990. https:\/\/doi.org\/10.1016\/j.biopha.2018.07.046","journal-title":"Biomed Pharmacother"},{"key":"10470_CR28","doi-asserted-by":"publisher","first-page":"2805","DOI":"10.3892\/mmr.2019.10485","volume":"20","author":"LN Ge","year":"2019","unstructured":"Ge LN, Yan L, Li C, Cheng K (2019) Bavachinin exhibits antitumor activity against non\u2013small cell lung cancer by targeting PPARgamma. Mol Med Rep 20:2805\u20132811. https:\/\/doi.org\/10.3892\/mmr.2019.10485","journal-title":"Mol Med Rep"},{"key":"10470_CR29","doi-asserted-by":"publisher","unstructured":"Dai L, Zhao T, Bisteau X, Sun W et al (2018) Modulation of Protein-Interaction States through the Cell Cycle. Cell 173, 1481\u20131494 e1413. https:\/\/doi.org\/10.1016\/j.cell.2018.03.065","DOI":"10.1016\/j.cell.2018.03.065"},{"key":"10470_CR30","doi-asserted-by":"publisher","unstructured":"P\u00f3voa AA, Teixeira E, Bella-Cueto MR, Melo M et al (2020) Clinicopathological Features as Prognostic Predictors of Poor Outcome in Papillary Thyroid Carcinoma. Cancers (Basel) 12. https:\/\/doi.org\/10.3390\/cancers12113186","DOI":"10.3390\/cancers12113186"},{"key":"10470_CR31","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1111\/cen.14316","volume":"94","author":"B Chen","year":"2021","unstructured":"Chen B, Shi Y, Xu Y, Zhang J (2021) The predictive value of coexisting BRAFV600E and TERT promoter mutations on poor outcomes and high tumour aggressiveness in papillary thyroid carcinoma: A systematic review and meta-analysis. Clin Endocrinol (Oxf) 94:731\u2013742. https:\/\/doi.org\/10.1111\/cen.14316","journal-title":"Clin Endocrinol (Oxf)"},{"key":"10470_CR32","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.molmed.2014.10.009","volume":"21","author":"KC Ohaegbulam","year":"2015","unstructured":"Ohaegbulam KC, Assal A, Lazar-Molnar E, Yao Y, Zang X (2015) Human cancer immunotherapy with antibodies to the PD-1 and PD-L1 pathway. Trends Mol Med 21:24\u201333. https:\/\/doi.org\/10.1016\/j.molmed.2014.10.009","journal-title":"Trends Mol Med"},{"key":"10470_CR33","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1186\/s12885-019-5380-3","volume":"19","author":"JM Mehnert","year":"2019","unstructured":"Mehnert JM, Varga A, Brose MS, Aggarwal RR et al (2019) Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with advanced, PD-L1-positive papillary or follicular thyroid cancer. BMC Cancer 19:196. https:\/\/doi.org\/10.1186\/s12885-019-5380-3","journal-title":"BMC Cancer"},{"key":"10470_CR34","doi-asserted-by":"publisher","first-page":"929091","DOI":"10.3389\/fendo.2022.929091","volume":"13","author":"A Garcia-Alvarez","year":"2022","unstructured":"Garcia-Alvarez A, Hernando J, Carmona-Alonso A, Capdevila J (2022) What is the status of immunotherapy in thyroid neoplasms? Front Endocrinol (Lausanne) 13:929091. https:\/\/doi.org\/10.3389\/fendo.2022.929091","journal-title":"Front Endocrinol (Lausanne)"},{"key":"10470_CR35","doi-asserted-by":"publisher","first-page":"1016208","DOI":"10.3389\/fimmu.2022.1016208","volume":"13","author":"D Espie","year":"2022","unstructured":"Espie D, Donnadieu E (2022) New insights into CAR T cell-mediated killing of tumor cells. Front Immunol 13:1016208. https:\/\/doi.org\/10.3389\/fimmu.2022.1016208","journal-title":"Front Immunol"},{"key":"10470_CR36","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1186\/s12905-023-02864-5","volume":"24","author":"J Zheng","year":"2024","unstructured":"Zheng J, Jiang S, Lin X, Wang H et al (2024) Comprehensive analyses of mitophagy-related genes and mitophagy-related lncRNAs for patients with ovarian cancer. BMC Womens Health 24:37. https:\/\/doi.org\/10.1186\/s12905-023-02864-5","journal-title":"BMC Womens Health"},{"key":"10470_CR37","doi-asserted-by":"publisher","first-page":"1623","DOI":"10.2147\/CCID.S410723","volume":"16","author":"Y Geng","year":"2023","unstructured":"Geng Y, Sun YJ, Song H, Miao QJ et al (2023) Construction and Identification of an NLR-Associated Prognostic Signature Revealing the Heterogeneous Immune Response in Skin Cutaneous Melanoma. Clin Cosmet Investig Dermatol 16:1623\u20131639. https:\/\/doi.org\/10.2147\/CCID.S410723","journal-title":"Clin Cosmet Investig Dermatol"},{"key":"10470_CR38","doi-asserted-by":"publisher","first-page":"2316","DOI":"10.1007\/s11427-024-2849-2","volume":"68","author":"N Lou","year":"2025","unstructured":"Lou N, Dai L, Gao R, Yang J et al (2025) Single-cell sequencing and spatial transcriptomics reveal FAS\u2009+\u2009T cell and autophagy-related signatures predicting chemoimmunotherapy response in diffuse large B-cell lymphoma patients. Sci China Life Sci 68:2316\u20132331. https:\/\/doi.org\/10.1007\/s11427-024-2849-2","journal-title":"Sci China Life Sci"},{"key":"10470_CR39","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1007\/s11033-025-11330-4","volume":"53","author":"S Bindu","year":"2025","unstructured":"Bindu S, Mukherjee O, Bibi R, George M, Sarkar K (2025) Interferon-alpha 2b (IFNalpha2b) enhances monocyte-derived dendritic cell maturation and Th1-skewed anti-tumor immunity in non-small cell lung cancer. Mol Biol Rep 53:165. https:\/\/doi.org\/10.1007\/s11033-025-11330-4","journal-title":"Mol Biol Rep"},{"key":"10470_CR40","doi-asserted-by":"publisher","first-page":"1718","DOI":"10.1158\/2159-8290.CD-21-1022","volume":"12","author":"B Hu","year":"2022","unstructured":"Hu B, Yu M, Ma X, Sun J et al (2022) IFNalpha Potentiates Anti-PD-1 Efficacy by Remodeling Glucose Metabolism in the Hepatocellular Carcinoma Microenvironment. Cancer Discov 12:1718\u20131741. https:\/\/doi.org\/10.1158\/2159-8290.CD-21-1022","journal-title":"Cancer Discov"},{"key":"10470_CR41","doi-asserted-by":"publisher","first-page":"e10936","DOI":"10.1002\/adma.202510936","volume":"37","author":"X Zheng","year":"2025","unstructured":"Zheng X, Lei S, Zeng Y, Chen L et al (2025) Peptide Coacervates with Metal-Phenolic Membranes Modulate Glucose Metabolism and Enhance Cancer Immunotherapy. Adv Mater 37:e10936. https:\/\/doi.org\/10.1002\/adma.202510936","journal-title":"Adv Mater"},{"key":"10470_CR42","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1111\/cge.13152","volume":"93","author":"M Umair","year":"2018","unstructured":"Umair M, Ullah A, Abbas S, Ahmad F et al (2018) First direct evidence of involvement of a homozygous loss-of-function variant in the EPS15L1 gene underlying split-hand\/split-foot malformation. Clin Genet 93:699\u2013702. https:\/\/doi.org\/10.1111\/cge.13152","journal-title":"Clin Genet"},{"key":"10470_CR43","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1038\/s41416-021-01340-x","volume":"125","author":"J Liang","year":"2021","unstructured":"Liang J, Jin Z, Kuang J, Feng H et al (2021) The role of anlotinib-mediated EGFR blockade in a positive feedback loop of CXCL11-EGF-EGFR signalling in anaplastic thyroid cancer angiogenesis. Br J Cancer 125:390\u2013401. https:\/\/doi.org\/10.1038\/s41416-021-01340-x","journal-title":"Br J Cancer"},{"key":"10470_CR44","doi-asserted-by":"publisher","first-page":"12618","DOI":"10.1093\/nar\/gkaa1119","volume":"48","author":"M Guo","year":"2020","unstructured":"Guo M, Xiao ZD, Dai Z, Zhu L et al (2020) The landscape of long noncoding RNA-involved and tumor-specific fusions across various cancers. Nucleic Acids Res 48:12618\u201312631. https:\/\/doi.org\/10.1093\/nar\/gkaa1119","journal-title":"Nucleic Acids Res"},{"key":"10470_CR45","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1007\/s12094-021-02753-z","volume":"24","author":"H Lu","year":"2022","unstructured":"Lu H, Zhu C, Chen Y, Ruan Y et al (2022) LncRNA ABHD11-AS1 promotes tumor progression in papillary thyroid carcinoma by regulating EPS15L1\/EGFR signaling pathway. Clin Transl Oncol 24:1124\u20131133. https:\/\/doi.org\/10.1007\/s12094-021-02753-z","journal-title":"Clin Transl Oncol"},{"key":"10470_CR46","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.cyto.2018.02.013","volume":"105","author":"E Motylewska","year":"2018","unstructured":"Motylewska E, St\u0119pie\u0144 T, Borkowska M, Kuzdak K et al (2018) Alteration in the serum concentrations of FGF19, FGFR4 and \u03b2Klotho in patients with thyroid cancer. Cytokine 105:32\u201336. https:\/\/doi.org\/10.1016\/j.cyto.2018.02.013","journal-title":"Cytokine"},{"key":"10470_CR47","doi-asserted-by":"publisher","first-page":"1222","DOI":"10.1080\/08820139.2021.1923734","volume":"51","author":"Y Jiang","year":"2022","unstructured":"Jiang Y, Mao X, Song R, Mu K et al (2022) Psoriasis Susceptibility 1 Candidate 1 (PSORS1C1) Polymorphism is Associated with Autoimmune Thyroid Disease in a Chinese Han Population. Immunol Invest 51:1222\u20131231. https:\/\/doi.org\/10.1080\/08820139.2021.1923734","journal-title":"Immunol Invest"},{"key":"10470_CR48","doi-asserted-by":"publisher","first-page":"e0169956","DOI":"10.1371\/journal.pone.0169956","volume":"12","author":"P Conigliaro","year":"2017","unstructured":"Conigliaro P, Ciccacci C, Politi C, Triggianese P et al (2017) Polymorphisms in STAT4, PTPN2, PSORS1C1 and TRAF3IP2 Genes Are Associated with the Response to TNF Inhibitors in Patients with Rheumatoid Arthritis. PLoS ONE 12:e0169956. https:\/\/doi.org\/10.1371\/journal.pone.0169956","journal-title":"PLoS ONE"},{"key":"10470_CR49","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.imlet.2013.06.001","volume":"153","author":"H Sun","year":"2013","unstructured":"Sun H, Xia Y, Wang L, Wang Y, Chang X (2013) PSORS1C1 may be involved in rheumatoid arthritis. Immunol Lett 153:9\u201314. https:\/\/doi.org\/10.1016\/j.imlet.2013.06.001","journal-title":"Immunol Lett"},{"key":"10470_CR50","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1186\/s13000-023-01362-4","volume":"18","author":"S Banerjee","year":"2023","unstructured":"Banerjee S, Nahar U, Dahiya D, Gupta R et al (2023) IL-17 A correlates with disease progression in papillary thyroid carcinoma. Diagn Pathol 18:93. https:\/\/doi.org\/10.1186\/s13000-023-01362-4","journal-title":"Diagn Pathol"},{"key":"10470_CR51","doi-asserted-by":"publisher","first-page":"100817","DOI":"10.1016\/j.jbior.2021.100817","volume":"82","author":"SA Hamila","year":"2021","unstructured":"Hamila SA, Ooms LM, Rodgers SJ, Mitchell CA (2021) The INPP4B paradox: Like PTEN, but different. Adv Biol Regul 82:100817. https:\/\/doi.org\/10.1016\/j.jbior.2021.100817","journal-title":"Adv Biol Regul"},{"key":"10470_CR52","doi-asserted-by":"publisher","unstructured":"Ghareghomi S, Habibi-Rezaei M, Arese M, Saso L, Moosavi-Movahedi AA (2022) Nrf2 Modulation in Breast Cancer. Biomedicines 10. https:\/\/doi.org\/10.3390\/biomedicines10102668","DOI":"10.3390\/biomedicines10102668"},{"key":"10470_CR53","doi-asserted-by":"publisher","first-page":"2636","DOI":"10.1002\/hed.25740","volume":"41","author":"C Means","year":"2019","unstructured":"Means C, Clayburgh DR, Maloney L, Sauer D et al (2019) Tumor immune microenvironment characteristics of papillary thyroid carcinoma are associated with histopathological aggressiveness and BRAF mutation status. Head Neck 41:2636\u20132646. https:\/\/doi.org\/10.1002\/hed.25740","journal-title":"Head Neck"},{"key":"10470_CR54","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1089\/thy.2024.0072","volume":"34","author":"A Kotwal","year":"2024","unstructured":"Kotwal A, Vance K, Hajric K, Yuil-Valdes A et al (2024) Characterization of Immune Infiltrate Along the Leading Edge of Differentiated Thyroid Cancer. Thyroid 34:999\u20131006. https:\/\/doi.org\/10.1089\/thy.2024.0072","journal-title":"Thyroid"},{"key":"10470_CR55","doi-asserted-by":"publisher","unstructured":"Milesi C, Alberici P, Pozzi B, Oldani A et al (2019) Redundant and nonredundant organismal functions of EPS15 and EPS15L1. Life Sci Alliance 2. https:\/\/doi.org\/10.26508\/lsa.201800273","DOI":"10.26508\/lsa.201800273"},{"key":"10470_CR56","doi-asserted-by":"publisher","DOI":"10.1002\/cac2.70052","author":"F Tian","year":"2025","unstructured":"Tian F, Huang J, Fan W, Li X et al (2025) m(6)A-modified EHD1 controls PD-L1 endosomal trafficking to modulate immune evasion and immunotherapy responses in lung adenocarcinoma. Cancer Commun (Lond). https:\/\/doi.org\/10.1002\/cac2.70052","journal-title":"Cancer Commun (Lond)"},{"key":"10470_CR57","doi-asserted-by":"publisher","first-page":"e89599","DOI":"10.1371\/journal.pone.0089599","volume":"9","author":"JM Bomberger","year":"2014","unstructured":"Bomberger JM, Coutermarsh BA, Barnaby RL, Sato JD et al (2014) Serum and glucocorticoid-inducible kinase1 increases plasma membrane wt-CFTR in human airway epithelial cells by inhibiting its endocytic retrieval. PLoS ONE 9:e89599. https:\/\/doi.org\/10.1371\/journal.pone.0089599","journal-title":"PLoS ONE"},{"key":"10470_CR58","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1186\/s12967-023-03977-z","volume":"21","author":"X Li","year":"2023","unstructured":"Li X, Wang Z, Jiao C, Zhang Y et al (2023) Hepatocyte SGK1 activated by hepatic ischemia-reperfusion promotes the recurrence of liver metastasis via IL-6\/STAT3. J Transl Med 21:121. https:\/\/doi.org\/10.1186\/s12967-023-03977-z","journal-title":"J Transl Med"},{"key":"10470_CR59","doi-asserted-by":"publisher","first-page":"e113795","DOI":"10.1371\/journal.pone.0113795","volume":"9","author":"HO Berdel","year":"2014","unstructured":"Berdel HO, Yin H, Liu JY, Grochowska K et al (2014) Targeting serum glucocorticoid-regulated kinase-1 in squamous cell carcinoma of the head and neck: a novel modality of local control. PLoS ONE 9:e113795. https:\/\/doi.org\/10.1371\/journal.pone.0113795","journal-title":"PLoS ONE"},{"key":"10470_CR60","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1681\/ASN.2010060681","volume":"22","author":"CJ Cheng","year":"2011","unstructured":"Cheng CJ, Huang CL (2011) Activation of PI3-kinase stimulates endocytosis of ROMK via Akt1\/SGK1-dependent phosphorylation of WNK1. J Am Soc Nephrol 22:460\u2013471. https:\/\/doi.org\/10.1681\/ASN.2010060681","journal-title":"J Am Soc Nephrol"},{"key":"10470_CR61","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1093\/bib\/bbt085","volume":"16","author":"HM Zhang","year":"2015","unstructured":"Zhang HM, Kuang S, Xiong X, Gao T et al (2015) Transcription factor and microRNA co-regulatory loops: important regulatory motifs in biological processes and diseases. Brief Bioinform 16:45\u201358. https:\/\/doi.org\/10.1093\/bib\/bbt085","journal-title":"Brief Bioinform"}],"container-title":["European Archives of Oto-Rhino-Laryngology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00405-026-10470-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00405-026-10470-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00405-026-10470-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T11:56:22Z","timestamp":1790337382000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00405-026-10470-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,27]]},"references-count":61,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["10470"],"URL":"https:\/\/doi.org\/10.1007\/s00405-026-10470-y","relation":{},"ISSN":["0937-4477","1434-4726"],"issn-type":[{"value":"0937-4477","type":"print"},{"value":"1434-4726","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,27]]},"assertion":[{"value":"26 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Ethical approval and consent were not required as this study was based on publicly available data.","order":1,"name":"Ethics","label":"Ethics approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.","order":2,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}}]}}